The 23% annualized share price decline underscores the risk of investing in unprofitable firms. The company's poor performance last year may suggest ongoing issues, as it was worse than the 11% annualized loss over the past five years. Prolonged share price weakness can be a negative indicator, though contrarian investors might want to investigate the stock for a potential turnaround.
NovoCure insiders sold $66k worth of shares in the last 3 months, indicating they may not see current share price as a bargain. Despite high insider ownership aligning interests with shareholders, history of share sales casts doubt on this optimistic outlook.
$ノボキュア(NVCR.US)$ Year NVCR is clearly over sold A LOT as 4 cancer drugs were approved by FDA with phase 3 trials having less than 200 patients enrolled since 2019 and Novocure's Lunar phase 3 trials have total 552 patients including 133 for TTF-ICIs cohort with unprecedented astonishing result on NSCLC. Drug Indication Number of...
ノボキュアに関するコメント
Long hold
Novocure highly likely will get FDA approval on NSCLC this year as 4 cancer drugs approved by FDA with phase 3 trials having less than 200 patients enrolled since 2019
Year
NVCR is clearly over sold A LOT as 4 cancer drugs were approved by FDA with phase 3 trials having less than 200 patients enrolled since 2019 and Novocure's Lunar phase 3 trials have total 552 patients including 133 for TTF-ICIs cohort with unprecedented astonishing result on NSCLC.
Drug
Indication
Number of...
まだコメントはありません